Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mentholatum seeks advisory committee review of analgesic patches/pads.

This article was originally published in The Tan Sheet

Executive Summary

MENTHOLATUM REQUESTS OTC ADVISORY PANEL REVIEW OF ANALGESIC PADS/PATCHES to discuss "scientific and legal issues" related to such products. In an Aug. 4 citizen petition to FDA, Mentholatum noted that the status of pad and patch OTC external analgesic products is "an industry-wide issue that has never been properly addressed in the external analgesic rulemaking." FDA should first reopen the administrative record for OTC external analgesics and then "submit the issue to the OTC advisory panel for evaluation," the company asserted.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084210

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel